MENU
+Compare
BMED
ETF ticker: NYSE ARCA
AS OF
Jul 11, 04:50 PM (EDT)
Price
$25.08
Change
-$0.35 (-1.38%)
Net Assets
4.02M

BMED stock forecast, quote, news & analysis

The investment seeks to maximize total return... Show more

Category: #Health
BMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BMED with price predictions
Jul 11, 2025

BMED in +0.70% Uptrend, advancing for three consecutive days on July 03, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BMED advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 30, 2025. You may want to consider a long position or call options on BMED as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BMED just turned positive on July 10, 2025. Looking at past instances where BMED's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 253 cases where BMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

BMED broke above its upper Bollinger Band on July 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Intuitive Surgical (NASDAQ:ISRG), Elevance Health (NYSE:ELV), Medtronic plc (NYSE:MDT), Bristol-Myers Squibb Co (NYSE:BMY), Boston Scientific Corp (NYSE:BSX).

Industry description

The investment seeks to maximize total return. Under normal market conditions, the fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities of companies principally engaged in the health sciences group of industries. While the fund will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants.

Market Cap

The average market capitalization across the iShares Health Innovation Active ETF ETF is 34.29B. The market cap for tickers in the group ranges from 102.43M to 380.22B. JNJ holds the highest valuation in this group at 380.22B. The lowest valued company is TCRX at 102.43M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Health Innovation Active ETF ETF was 2%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was 0%. MTSR experienced the highest price growth at 36%, while GPCR experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the iShares Health Innovation Active ETF ETF was 34%. For the same stocks of the ETF, the average monthly volume growth was -21% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 75
Price Growth Rating: 50
SMR Rating: 78
Profit Risk Rating: 79
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
BMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
BlackRock ETF Trust100 BELLEVUE PARKWAY
Phone
N/A
Web
www.blackrock.com